Wall Street analysts forecast that Masimo Co. (NASDAQ:MASI) will post sales of $242.56 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Masimo’s earnings, with the lowest sales estimate coming in at $241.73 million and the highest estimate coming in at $243.00 million. Masimo posted sales of $223.13 million during the same quarter last year, which suggests a positive year over year growth rate of 8.7%. The firm is scheduled to report its next earnings report on Tuesday, February 25th.
On average, analysts expect that Masimo will report full-year sales of $932.91 million for the current year, with estimates ranging from $932.06 million to $933.40 million. For the next financial year, analysts anticipate that the firm will post sales of $1.02 billion, with estimates ranging from $1.02 billion to $1.03 billion. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Masimo.
Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The firm had revenue of $229.01 million during the quarter, compared to analysts’ expectations of $221.92 million. Masimo had a return on equity of 17.32% and a net margin of 20.83%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.71 EPS.
Several equities research analysts have issued reports on the company. Stifel Nicolaus lifted their price objective on Masimo from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. BTIG Research restated a “hold” rating on shares of Masimo in a report on Thursday, August 1st. ValuEngine downgraded Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. BidaskClub downgraded Masimo from a “hold” rating to a “sell” rating in a report on Friday. Finally, UBS Group lifted their price objective on Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $159.25.
In other news, CFO Micah W. Young sold 12,087 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $150.02, for a total value of $1,813,291.74. Following the completion of the sale, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $1,500,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Yongsam Lee sold 4,981 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $153.62, for a total value of $765,181.22. Following the completion of the sale, the executive vice president now owns 76,857 shares of the company’s stock, valued at $11,806,772.34. The disclosure for this sale can be found here. Insiders have sold a total of 40,600 shares of company stock worth $6,094,362 over the last 90 days. 11.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Capital Investment Advisory Services LLC bought a new stake in shares of Masimo in the 2nd quarter valued at approximately $25,000. Financial Gravity Wealth Inc. bought a new stake in shares of Masimo in the 2nd quarter valued at approximately $31,000. Private Capital Group LLC increased its holdings in shares of Masimo by 92.1% in the 2nd quarter. Private Capital Group LLC now owns 340 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 163 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in shares of Masimo by 45.7% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 236 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 74 shares during the last quarter. Finally, Pearl River Capital LLC bought a new stake in shares of Masimo in the 2nd quarter valued at approximately $37,000. Institutional investors and hedge funds own 82.75% of the company’s stock.
NASDAQ:MASI traded up $1.57 during mid-day trading on Monday, reaching $142.95. The company’s stock had a trading volume of 310,600 shares, compared to its average volume of 391,190. Masimo has a twelve month low of $98.23 and a twelve month high of $160.25. The company’s fifty day simple moving average is $146.39 and its two-hundred day simple moving average is $145.98. The stock has a market cap of $7.58 billion, a P/E ratio of 47.18, a P/E/G ratio of 1.95 and a beta of 1.14.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.